Coles starts FY23 with modest sales growth

Nick Sundich Nick Sundich, October 26, 2022

Coles (ASX:COL) reported its Q1 results for FY23 and these turned out positive for the company. The headline revenue growth figure was only 1.3%, but impressive in a time of high inflation and expenditure on hospitality higher than 12 months ago. 

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

 

Coles records $9.9bn in sales

Coles’ revenue for the 13 weeks from 27 June to 25 September was $9.9bn. $8.8bn of this came from supermarkets, $836m from liquor and $284m from Express.

Liquor was down by 4.3% compared to the prior corresponding period which was inflated by lockdowns. But Express was 8.4% higher as people drove more than they could during lockdowns. Supermarkets was 1.6% higher than the prior corresponding period. 

 

Will the good times continue?

Coles’ results came in spite of the ‘Dropped & Locked’ initiative, which caps prices. In one sense, the results are positive.

But it is important to note, today’s results did not record mention bottom line figures, which would arguably give a clearer picture as to the impacts. Coles may not be as impacted by rising costs being a price setter, but it may be unable to avoid an impact altogether. Investors have sent shares down 1.8% this morning, arguably expecting a better result because supermarkets are the ultimate consumer staple category on the share market.

 

Coles (ASX:COL) share price chart (Graph: TradingView)

 

We think it will be interesting to compare its results to that of Woolworths, although its competitor reports on a different calendar so will not be updating shareholders until next month. 

 

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

No credit card needed and the trial expires automatically.

 

 

Blog Categories

Recent Posts

rule of 72

Rule of 72: Here’s how investors can use it to their advantage

Here’s why The Rule of 72 might be useful to consider when investing in Stocks Investing in stocks can be…

Novo Nordisk

Novo Nordisk (CPH: NOVO-B): It’s not all smooth sailing for the US$400bn company behind obesity drug Ozempic

Not many 100-year old healthcare stocks see a sudden 30% jump in sales in one year, but Novo Nordisk (CPH:…

Bapcor

Bapcor (ASX:BAP): Its been a horror week with a 3rd profit downgrade in less than a year

This week investors in Bapcor (ASX:BAP) saw a 3rd profit downgrade in less than a year and its CEO-elect walk…